1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)

• Tuomo Alanko,
• Akseli Hemminki,
• Víctor Cervera-Carrascón,
• João Santos,
• Riikka Havunen,
• Juha Kononen,
• Jorma Sormunen,
• Katriina Peltola,
• Riitta Korpisaari,
• Susanna Juteau,
• Marjut Jaakkola,
• Suvi Sorsa,
• Santeri A Pakola,
• James Clubb,
• Elise Jirovec,
• Dafne CA Quixabeira,
• Lyna Haybout,
• Claudia Kistler,
• Tatiana V Kudling

Affiliations

Tuomo Alanko

4Docrates Cancer Center, Helsinki, Finland

Akseli Hemminki

3TILT Biotherapeutics, Helsinki, Finland

Víctor Cervera-Carrascón

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

João Santos

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Riikka Havunen

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Juha Kononen

4Docrates Cancer Center, Helsinki, Finland

Jorma Sormunen

4Docrates Cancer Center, Helsinki, Finland

Katriina Peltola

3Comprehensive Cancer Centre, Helsinki, Finland

Riitta Korpisaari

4Docrates Cancer Center, Helsinki, Finland

Susanna Juteau

5HUS Helsinki University Hospital, Helsinki, Finland

Marjut Jaakkola

5HUS Helsinki University Hospital, Helsinki, Finland

Suvi Sorsa

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Santeri A Pakola

3Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland

James Clubb

1TILT Biotherapeutics Ltd, Helsinki, Finland

Elise Jirovec

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Dafne CA Quixabeira

1TILT Biotherapeutics Ltd, Helsinki, Finland

Lyna Haybout

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Claudia Kistler

2TILT Biotherapeutics Ltd, Helsinki, Finland

Tatiana V Kudling

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland